1. S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
   Mike F. Burbridge et al, 2013, Molecular Cancer Therapeutics CrossRef
2. Complex Oncogenic Signaling Networks Regulate Brain Tumor‐Initiating Cells and Their Progenies: Pivotal Roles of Wild‐Type EGFR, EGFRvIII Mutant and Hedgehog Cascades and Novel Multitargeted Therapies
   Murielle Mimeault et al, 2011, Brain Pathology CrossRef
3. Correlation of low SLC22A18 expression with poor prognosis in patients with glioma
   Sheng-Hua Chu et al, 2012, Journal of Clinical Neuroscience CrossRef
4. Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy
   Sheng-Hua Chu et al, 2013, Journal of Translational Medicine CrossRef
5. The role of MET in chemotherapy resistance
   Georgina E. Wood et al, 2021, Oncogene CrossRef
6. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma
   Sheng-Hua Chu et al, 2011, Journal of Translational Medicine CrossRef
7. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells
   Biao Yang et al, 2018, Cancer Gene Therapy CrossRef